Ceftriaxone Production
Rafarma is pleased to announce commencement of production of the antibiotic Ceftriaxone. Ceftriaxone treats inflammatory infections of the organs of the abdominal cavity, including peritonitis, as well as inflammatory diseases of the gastrointestinal and bile-excreting tracts. According to 2011 official statistics, the market for Ceftriaxone in Russia is estimated at more than $51 million (USD) annually. As a participant in the Russian Federal Program for Domestic-Produced Vital Drugs, Rafarma intends to take as much as 50% of the Russian market for Ceftriaxone.
New National and Regional Distribution Contracts
ZAO ?SIA International? and the Russian national retail chain OAO ?A5 Pharmacy Ltd.? have entered into long-term distribution contracts giving Rafarma an overnight national presence in the Russian Federation retail pharmaceutical market.
CEO David Anderson stated, ?Rafarma's increase in production and penetration of market share becomes even more assured with the 17 national distributors we have signed to long term agreements. These contracts were an integral part of Rafarma?s expansion plan and will play a vital role in the expansion of operations. Rafarma has positioned itself to become one of the five leading pharmaceutical companies in the Russian Federation.?
Mr. Anderson went on to say, ?The agreements with these drug store chains and pharmaceutical supply companies moves Rafarma in a very positive direction and also shows the respect these companies have for Rafarma. I am extremely pleased that we get to work with such qualified partners that have the confidence in Rafarma to lock in long-term contracts."
ABOUT Ceftriaxone: Ceftriaxone is produced for injections and will be packaged in 10 ml. bottles with single gram dosages. Ceftriaxone shall be produced in Unit 2 of Rafarma?s Terbuni plant. Unit 2 specializes in the production of cephalosporin-based products and bottle-packaged injection products.
ABOUT Rafarma Pharmaceuticals: Rafarma Pharmaceuticals is a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals, in addition to its own line of proprietary products that are approved by the Ministry of Health of the Russian Federation.
ABOUT ZAO ?SIA International? ZAO SIA International, is currently ranked as the No. 1 pharmaceutical wholesaler and marketer in the Russian pharmaceutical marketplace, with a market share exceeding 20%.
ABOUT OAO ?A5 Pharmacy Ltd.? A5 Pharmacy Chain has established itself as a leading brand in the Russian pharmacy sector with a strong track record of organic growth. The chain comprises different formats of pharmacies, from pharmacy kiosks to premium stores in the center of Moscow. A5?s well-thought out strategy and strong execution of its customer value proposition have established the chain?s leadership and won awards and recognition in independent industry rankings.
For Investor Relations, contact Mr. William Nalley, Orsay Groupe, info@orsaygroupe.com, phone 305-515-8077.
Safe Harbor: Statements contained in this news release which are not
historical facts may be forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the fact that they do not relate strictly to
historical or current facts. They often include words like "believe,"
"expect," "anticipate," "estimate" and
"intend" or future or conditional verbs such as "will,"
"would," "should," "could" or "may." We
undertake no obligation to update any forward-looking statements.